MediLexicon Logo
MediLexicon Logo
Abbreviations        Abbrev Definitions        Dictionary        ICD Codes        Equipment        Hospitals        Drugs        More..

Inform HER-2/neu breast cancer test

Company: Oncor
Approval Status: Approved January 1998
Treatment for: breast cancer prediction
Areas: Diabetes / Endocrinology; Pregnancy & Gynecology; Cancer & Oncology

| General Information | Clinical Results |

General Information

Inform has been approved for the prediction of breast cancer. It is a gene-based test which identifies the presence or absence of increased copies of the HER-2/neu gene, a gene known to have an increased presence in a particularly aggressive form of breast cancer.

Clinical Results

In studies with early breast cancer patients, 69% of the women who tested positive for the HER-2/neu gene survived five years after surgery compared with 97% of patients with negative test results.

< back to top

Inform HER-2/neu breast cancer test Drug Information

The Inform Her-2/neu Breast Cancer Test drug information shown above is licensed from Thomson CenterWatch. The information provided here is for general educational purposes only and does not constitute medical or pharmaceutical advice which should be sought from qualified medical and pharmaceutical advisers.

MediLexicon International Ltd Logo

Privacy Policy   |    Disclaimer   |    Contact / Feedback

MediLexicon International Ltd
Bexhill-on-Sea, UK
MediLexicon International Ltd © 2004-2016 All rights reserved.